Vaughan David Investments LLC IL Boosts Stock Holdings in Merck & Co., Inc. $MRK

Vaughan David Investments LLC IL increased its stake in Merck & Co., Inc. (NYSE:MRK) by 2.1% during the 3rd quarter, Holdings Channel reports. The fund owned 412,241 shares of the company’s stock after purchasing an additional 8,664 shares during the quarter. Vaughan David Investments LLC IL’s holdings in Merck & Co., Inc. were worth $34,599,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dakota Community Bank & Trust NA boosted its stake in shares of Merck & Co., Inc. by 3.4% in the 3rd quarter. Dakota Community Bank & Trust NA now owns 3,566 shares of the company’s stock valued at $299,000 after buying an additional 116 shares during the period. Security National Bank of Sioux City Iowa IA increased its stake in shares of Merck & Co., Inc. by 3.6% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 3,402 shares of the company’s stock worth $286,000 after buying an additional 119 shares during the period. Investors Research Corp raised its holdings in Merck & Co., Inc. by 1.3% in the third quarter. Investors Research Corp now owns 9,325 shares of the company’s stock valued at $783,000 after acquiring an additional 120 shares in the last quarter. Trust Point Inc. lifted its stake in Merck & Co., Inc. by 0.8% in the third quarter. Trust Point Inc. now owns 14,834 shares of the company’s stock worth $1,245,000 after acquiring an additional 120 shares during the last quarter. Finally, Nicolet Bankshares Inc. raised its holdings in shares of Merck & Co., Inc. by 2.0% in the 2nd quarter. Nicolet Bankshares Inc. now owns 6,169 shares of the company’s stock valued at $488,000 after purchasing an additional 121 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the sale, the executive vice president directly owned 24,578 shares of the company’s stock, valued at $2,054,475.02. This represents a 25.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $108.89 on Tuesday. The firm’s fifty day simple moving average is $102.54 and its 200-day simple moving average is $90.34. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $112.90. The stock has a market capitalization of $270.27 billion, a price-to-earnings ratio of 14.38, a PEG ratio of 1.18 and a beta of 0.29. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.66 and a quick ratio of 1.44.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.94 earnings per share for the quarter, missing analysts’ consensus estimates of $2.08 by ($0.14). Merck & Co., Inc. had a return on equity of 44.54% and a net margin of 29.63%. As a group, equities analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 8th. Investors of record on Monday, December 15th were given a $0.85 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.81. The ex-dividend date was Monday, December 15th. This represents a $3.40 annualized dividend and a yield of 3.1%. Merck & Co., Inc.’s payout ratio is presently 44.91%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Five?year Phase 2b data show Merck’s KEYTRUDA combined with Moderna’s individualized mRNA vaccine (intismeran autogene / mRNA?4157) reduced the risk of recurrence or death by ~49% in high?risk melanoma after surgery — a durable, clinically meaningful result that supports further late?stage development and could materially expand Merck’s oncology franchise if confirmed. Moderna, Merck’s skin cancer vaccine shows sustained benefit after five years
• Positive Sentiment: Additional coverage and company release reinforce the same five?year efficacy signal and note ongoing Phase 2/3 studies across multiple tumor types — newsflow that could drive re?rating of MRK’s growth outlook in oncology. Moderna, Merck Report Positive Results From Cancer-Vaccine Study
• Positive Sentiment: Wells Fargo reaffirmed its Buy rating on Merck, signaling continued analyst conviction in the stock’s longer?term fundamentals and pipeline potential. Wells Fargo Reaffirms Their Buy Rating on Merck & Company (MRK)
• Neutral Sentiment: Industry writeups and buy?and?hold pieces highlight MRK as a durable dividend and healthcare franchise pick — supportive for steady investor interest but unlikely to move the stock materially by itself. 3 “Forever Stocks” to Hold When the Market Won’t Sit Still (MRK)
• Neutral Sentiment: Analyst/market commentary pieces (e.g., “poised for breakout” profiles) may support momentum if follow?through comes from M&A or trial advancement, but they are opinion?based. Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion
• Negative Sentiment: Insider/insider?related activity: a report that Rep. Julie Johnson sold MRK shares can create short?term selling pressure or headlines; generally a limited signal for a large, diversified pharma but worth noting. Rep. Julie Johnson Sells Merck & Co., Inc. (NYSE:MRK) Shares

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MRK shares. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their target price for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Zacks Research cut Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. Citigroup upped their price target on Merck & Co., Inc. from $95.00 to $110.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a report on Thursday, January 8th. Finally, Bank of America upped their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $112.87.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.